Phase 2Completed
A Study to Evaluate Antiviral Activity of Darunavir + Ritonavir in HIV-1 Infected Adolescents (DIONE)
A Phase II, Open-Label Trial, to Evaluate Pharmacokinetics, Safety, Tolerability and Antiviral Activity of Drv/Rtv Once Daily in Treatment-Naive HIV-1 Infected Adolescents Aged Between 12 and < 18 Years
- Sponsor
- Tibotec Pharmaceuticals, Ireland (Industry)
- Enrollment
- 12 enrolled
- Conditions
- HIV-1 Infection
- Interventions
- darunavir; ritonavir; zidovudine; lamivudine; abacavir
- Ages
- children, adults
- Registry
- NCT00915655, EUCTR2008-004631-37
Full record on ClinicalTrials.gov
From the registry
The purpose of this study is to evaluate pharmacokinetics (what body does to medication), safety, tolerability, and efficacy (effectiveness) of darunavir with low-dose ritonavir (DRV/rtv) administered once daily, in combination with an investigator-selected background regimen consisting of other antiretrovirals (ARVs) ie, 2 nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), in treatment-naive (never treated before) HIV-1 infected adolescents aged from 12 to \<18 years and weighing at least 40 kg.
Primary outcomes
- Virological Response[Viral Load <50 Copies/mL, TLOVR]
History
Last registry update
Results first posted
Study completion
Primary completion
Started
Registered